Walvax Biotechnology Co (300142.SZ) Stock Price
Walvax Biotechnology Co Price
Revenue has compounded at 17.6% per year over the past 18 years to 2.41 B CNY. Earnings per share have grown at 19.3% per year over the last 18 years. Walvax Biotechnology Co's net margin stands at 7.4%, down from 12.4% several years earlier. Walvax Biotechnology Co currently offers a dividend yield of about 0.08%. The payout ratio is around 9% of earnings. Analysts set a median price target of 7.14 CNY, implying 46.2% below the current price. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.
Walvax Biotechnology Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Walvax Biotechnology Co business model & stock analysis
Frequently asked questions about Walvax Biotechnology Co
The business model of Walvax Biotechnology Co Ltd is focused on the research, development, production, and sales of biopharmaceutical products. The company primarily engages in the manufacturing and distribution of vaccines, including pediatric vaccines, adult vaccines, and specialized vaccines. With a strong emphasis on quality control and technological innovation, Walvax Biotechnology aims to provide safe and effective immunization solutions to combat various diseases and improve public health. Through its comprehensive product portfolio and strategic partnerships, the company strives to contribute to the advancement of the biotechnology industry and meet the growing global demand for vaccines.
Walvax Biotechnology Co Ltd is primarily active in the biotechnology industry.
The main competitors of Walvax Biotechnology Co Ltd in the market include companies such as Sinovac Biotech Co Ltd, CanSino Biologics Inc, Beijing Tiantan Biological Products Co Ltd, and Hualan Biological Engineering Inc.
Walvax Biotechnology Co Ltd, founded in 2004, is a prominent biopharmaceutical company based in China. With a focus on research, development, production, and sales of vaccines, the company operates across various therapeutic areas. Walvax Biotechnology has played a significant role in advancing public health by contributing to the prevention and control of infectious diseases through its innovative vaccine solutions. As a leading player in the industry, the company is committed to delivering high-quality vaccines with a strong emphasis on safety and efficacy. With its rich history and expertise in biotechnology, Walvax Biotechnology Co Ltd continues to contribute to global healthcare and vaccine development.
Walvax Biotechnology Co Ltd has accomplished several significant milestones throughout its operations. The company has successfully developed and produced a range of high-quality pharmaceutical products, including vaccines, diagnostic reagents, and biological products. They have also established strong partnerships with leading global pharmaceutical organizations, contributing to the growth and recognition of their brand. Walvax Biotechnology Co Ltd has obtained various certifications and accreditations, ensuring the safety and effectiveness of its products. With a commitment to innovation and research, the company continually strives to improve healthcare outcomes and make valuable contributions to the medical industry.
Walvax Biotechnology Co Ltd is primarily present in China. As a leading biotech company, Walvax operates within the country and has its headquarters in the city of Kunming, Yunnan province. With a focus on vaccine development, manufacturing, and distribution, Walvax has a strong presence within the domestic market. It collaborates with various governmental organizations, healthcare providers, and research institutions in China to ensure the availability and accessibility of its life-saving vaccines. While Walvax has primarily targeted the Chinese market, its influence and partnerships may extend beyond the regional boundaries in the future as it continues to expand its capabilities and offerings.
Walvax Biotechnology Co Ltd represents a set of values and corporate philosophy that drive its operations. The company prioritizes innovation, constantly seeking breakthroughs in vaccine research and development. With a deep commitment to public health, Walvax Biotechnology Co Ltd emphasizes the importance of safety, efficacy, and quality in its products. By adhering to strict ethical standards, the company ensures utmost integrity in its operations. With a customer-centric approach, Walvax Biotechnology Co Ltd aims to meet the diverse needs of healthcare professionals and patients. As a trusted name in the biotechnology industry, Walvax Biotechnology Co Ltd continuously strives for excellence in scientific advancement and patient care.
Analysts currently set an average price target of 7.14 CNY for the Walvax Biotechnology Co stock (median: 7.14 CNY), implying -46.2 % versus the latest price. The consensus is based on 6 analyst ratings.
6 analysts currently rate the Walvax Biotechnology Co stock: 0 recommend buying, 2 holding and 4 selling. For 2026, analysts expect Walvax Biotechnology Co to generate revenue of 1.88 B CNY and earnings per share of 0.03 CNY.
Converted at the current exchange rate, the Walvax Biotechnology Co share trades at 1.76 EUR (13.27 CNY).
The Walvax Biotechnology Co share (300142.SZ) is listed on 2 stock exchanges, including: Shenzhen (300142.SZ), Frankfurt (MM9.F).
Walvax Biotechnology Co Ltd is a Chinese company specializing in the research, development, production, and distribution of vaccines and biotechnological products. The company was founded in 2001 and is headquartered in Beijing. The company is divided into various divisions. The first division is research and development. Walvax Biotechnology invests a high proportion of its revenue in researching and developing new vaccines and biotechnological products. To remain competitive, the company works with the latest technology and collaborates with renowned institutes and partners both domestically and internationally. The second division is production. Walvax Biotechnology has a huge production facility in Yunnan with specialized facilities and equipment. The facility meets international standards and is capable of producing a large number of vaccines and biotechnological products. The facility has a production capacity of 150 million doses of vaccines per year. The third division is distribution. Walvax Biotechnology has a network of distribution partners across China. The products are sold through hospitals, clinics, and pharmacies. The company also operates an e-commerce system to sell its products online. Walvax Biotechnology offers a wide range of vaccines and biotechnological products. The company has developed vaccines against polio, hepatitis A and B, rabies, meningitis, HPV, and influenza. Additionally, the company has also developed biotechnological products such as recombinant human interferon alpha-2b and recombinant human epidermal growth factor. Walvax Biotechnology is also working on developing vaccines against COVID-19 and other diseases. The business model of Walvax Biotechnology is based on researching and developing new vaccines and biotechnological products. The company regularly invests in research and development to remain competitive. The enormous production capacity ensures that the company can provide its customers with a continuous supply of vaccines and biotechnological products. The network of distribution partners across China allows the company to sell its products on a large scale. In this highly regulated and competitive market, the leadership of Walvax Biotechnology is always striving to develop new vaccines and biotechnological products to meet the needs of customers. The company is committed to meeting the highest standards in quality and safety and offering its products at the best prices. In conclusion, Walvax Biotechnology Co Ltd is a leading Chinese company in the field of biotechnological products and vaccines. The company specializes in the research, development, production, and distribution of vaccines and biotechnological products. The company invests a significant portion of its revenue in research and development to meet the needs of customers. The enormous production capacity and network of distribution partners across China ensure a continuous supply of high-quality vaccines and biotechnological products.
The expected revenue of Walvax Biotechnology Co is 1.88 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Walvax Biotechnology Co is 48.00 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Walvax Biotechnology Co is currently 442.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Walvax Biotechnology Co stock.
The price-to-sales ratio (P/S) of Walvax Biotechnology Co is currently 11.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Walvax Biotechnology Co stock.
The Eulerpool Quality Score for Walvax Biotechnology Co is 4/10.
The ISIN of Walvax Biotechnology Co is CNE100000WN2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Walvax Biotechnology Co is 300142.SZ. The ticker symbol is used to trade Walvax Biotechnology Co shares on the stock exchange.
Walvax Biotechnology Co stock
Walvax Biotechnology Co Peer Group
Walvax Biotechnology Co Ticker
Walvax Biotechnology Co FIGI
All fundamentals and in-depth analysis of Walvax Biotechnology Co
Our stock analysis for Walvax Biotechnology Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Walvax Biotechnology Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.